{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-031061","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.547272+00:00","generated_at":"2026-06-11T01:14:56.569248+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BriaCell closes spinout of BriaPro to shareholders; retains 66.6% stake","bullets":["Closed plan of arrangement spinning out Bria-TILsRx™ and PKCδ inhibitors to BriaPro.","Shareholders receive one BriaPro share and one new BriaCell share per existing share.","BriaCell now owns ~66.6% (31,963,452 shares) of BriaPro's outstanding shares.","BriaPro becomes unlisted reporting issuer in Canada; BriaCell remains on Nasdaq and TSX.","New BriaCell common shares expected to trade on or about Sept 5, 2023 under 'BCT'."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-031061","json":"https://secwatch.observer/filing/0001493152-23-031061.json","markdown":"https://secwatch.observer/filing/0001493152-23-031061.md","text":"https://secwatch.observer/filing/0001493152-23-031061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223031061/0001493152-23-031061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223031061/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:14:56.569248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}